Poison Put Bond Covenants as a Takeover Defense

A poison put bond covenant embeds a put option into a company’s outstanding debt, allowing bondholders to force the issuer to repay their bonds at par value if the company undergoes a change of control. By raising the immediate cash requirement of an acquisition, poison puts increase the effective cost and complexity of a hostile bid, making some takeover attempts economically unfeasible.

How a Poison Put Works

When a company issues bonds with a poison put covenant, it grants bondholders the right—but not the obligation—to sell their bonds back to the company at par (usually 100% of face value) if a triggering event occurs. The triggering event is typically defined as a “change of control,” which might mean:

• Acquisition of more than 50% of voting shares
• Merger or consolidation where the original shareholders own less than 50% of the merged entity
• Loss of a majority of the board of directors in a hostile manner
• Sale of substantially all assets

When the put is exercised, the company must pay bondholders the full par amount immediately—whether or not the bonds were trading below par in the secondary market. This obligation does not disappear if the acquirer assumes the debt; it persists as a liability of the successor entity.

Why Acquirers Find Poison Puts Costly

An acquirer financing a hostile bid typically relies on a mix of cash, debt, and equity. If the target company has issued bonds with poison put covenants, the acquirer must account for a sudden, large cash outflow at closing: the aggregate par value of all put bonds.

Example scenario: Target Corp has $500 million in outstanding bonds with poison puts. The acquirer plans a $3 billion all-cash acquisition. Upon closing, the acquirer must immediately pay $500 million to retire the put bonds, reducing available cash for integration costs or increasing the effective price tag of the deal.

This burden is especially acute for leveraged buyouts, where the acquirer already carries high debt levels. A poison put can mean the difference between a financeable deal and one that breaches debt covenants or exceeds prudent leverage limits.

Poison Puts Versus Other Takeover Defenses

Poison puts operate differently from other common defenses:

• Poison pills (shareholder rights plans): Dilute the acquirer’s ownership stake by issuing cheap shares to existing shareholders. They delay deals and encourage negotiation but do not require immediate cash from the acquirer.
• Golden parachutes: Expensive severance payments to executives that boost deal cost but do not force debt repayment.
• Staggered boards: Slow the pace of board replacement, buying time for the board to explore alternatives or negotiate better terms.

Poison puts are unique because they operate through debt holders, not shareholders, and they force actual cash outflow rather than just making a deal slower or more dilutive. This makes them particularly effective against cash-poor or leveraged bidders.

The Bondholder Perspective

Bondholders benefit from poison puts because they gain liquidity and price protection. If the company is acquired by a weaker credit, the new owner might be expected to pay down debt or refinance at worse terms. The put allows bondholders to exit at par—avoiding that risk. In a strong M&A market, when better-rated acquirers are buying, bondholders might still exercise the put to lock in par value and redeploy capital elsewhere at higher yields.

From the issuer’s perspective, the poison put is a sweetener that lowers the coupon the company must offer when issuing the bonds. Investors accept a lower yield because they gain the put option—a valuable insurance policy.

Pricing and Disclosure

The presence of a poison put covenant typically requires:

• Disclosure in the bond prospectus: The exact definition of “change of control,” the par value at which the put can be exercised, any grace periods, and any conditions (e.g., rating downgrades that also trigger the put).
• Accounting impact: The company must disclose contingent debt obligations in its footnotes, making the potential liability visible to equity investors and other creditors.
• Coupon reduction: Because the put is valuable to bondholders, issuers typically offer 0.25–0.5% lower coupon than otherwise required.

Rating agencies factor poison puts into their analysis. They reduce the likelihood of a smooth debt refinance post-acquisition, which can affect both the target’s and the acquirer’s credit ratings.

Limitations and Workarounds

Poison puts do not guarantee a deal will not happen—they make it more expensive and slower. Determined acquirers can:

• Negotiate with bondholders: Offer a slightly higher repayment price (e.g., 101% of par) to convince holders not to exercise the put.
• Refinance the debt: If the acquirer’s credit is strong, it may refinance the put bonds at market rates post-acquisition, though the refinancing must happen after bondholders have already exercised their puts.
• Amend the bonds: In some cases, the target company might persuade bondholders to waive or modify the poison put covenant before the acquisition is announced—a time-consuming process that signals vulnerability.

The clause also does not protect against a tender offer or a competing bidder strategy that makes the target’s board prefer the sale, reducing the company’s incentive to invoke other defenses.

See also